423 Molecular Markers as Determinants of Value in Glioma Surgery: A Cost-Effectiveness Analysis of IDH Mutation and MGMT Methylation Status

View at publisher Summarise with VIRAT
Authors: Danyal Ahmed Quraishi, Advith Sarikonda, Dwight Mitchell, Ashmal Sami, Steven R. Glener, Matthews Lan, Arbaz A. Momin, Emily L. Isch, Nicholas Clark, James J. Evans, Kevin D. Judy, Christopher J. Farrell
+1 more Ahilan Sivaganesan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: While molecular profiling has revolutionized glioma classification and prognostication, its impact on surgical cost-effectiveness remains unexplored. This study investigates how molecular markers—specifically IDH mutation and MGMT methylation status—influence the value of glioma surgery using the Operative Value index (OVI), defined as quality-adjusted life years (QALYs) achieved per $1,000 spent intraoperatively. METHODS: We analyzed 176 consecutive glioma resections (2017-2022) performed at our institution. Intraoperative costs were calculated using time-driven activity-based costing (TDABC) methodology. QALYs were derived from progression-free survival (PFS) and 6-month postoperative Karnofsky Performance Status. OVI was calculated by dividing QALYs by cost (per $1,000). Multivariable linear regression models were constructed to identify independent predictors of OVI while controlling for potential confounders, including tumor characteristics, resection extent, operative variables, and patient comorbidities including smoking, hypertension, diabetes, etc. RESULTS: In univariate analysis, IDH-mutant gliomas demonstrated significantly higher OVI compared to IDH-wildtype tumors (median: 0.29 vs. 0.12, p < 0.001). After multivariable adjustment of confounders, IDH mutation remained an independent predictor of higher OVI (B = 0.123, p = 0.057), with IDH-mutant tumors achieving 47% higher adjusted value than IDH-wildtype tumors. MGMT methylation showed a positive but non-significant association with OVI (B = 0.024, p =0.552). Among molecular profiles, IDH-mutant/MGMT-methylated tumors yielded the highest adjusted mean OVI (0.231), approximately 2.8 times greater than IDH-wildtype/MGMT-unmethylated tumors (0.084). CONCLUSIONS: This study establishes that IDH mutation status is independently associated with surgical value in glioma resection, after comprehensive adjustment for confounding variables. While total costs were similar between IDH-mutant and wildtype tumors, the outcomes achieved per dollar spent differed substantially. These findings suggest that molecular characteristics should be incorporated into value-based surgical decision-making frameworks and may help optimize resource allocation in neuro-oncology.

Fields of Study & Subjects

Glioma Diagnosis and Treatment Health Systems Economic Evaluations Quality of Life Economic and Financial Impacts of Cancer

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
120–121
Publication date
26 March 2026
Language
EN